{
    "clinical_study": {
        "@rank": "109461", 
        "arm_group": [
            {
                "arm_group_label": "Paracetamol", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators  predict that giving patients paracetamol in the operative period will\n      reduce their need for opioid pain reducers in the post operative setting."
        }, 
        "brief_title": "Morphine-sparing Effect of Intravenous Paracetamol for Post-operative Pain Management Following Laparoscopic Gastric Banding in Morbidly Obese Patients", 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Pain, Postoperative"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed as a population-based prospective, double blind cohort study. A\n      prospective cohort of patients admitted to laparoscopic  gastric banding due to morbid\n      obesity\n\n      STUDY GOALS\n\n        -  To evaluate the morphine-sparing effect of paracetamol IV in obese patients undergoing\n           bariatric surgery.\n\n        -  To identify potential ability of paracetamol IV to attenuate or relief  postoperative\n           pain in obesity patient undergoing bariatric  surgery\n\n        -  To determine effectiveness of paracetamol IV to reduce postoperative complication rate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years\n\n          -  Patients admitted for laparoscopic gastric banding\n\n          -  Elective surgery\n\n          -  BMI > 40\n\n          -  ASA (American Society Anesthesiologists perioperative risk stratification) class 1-2\n\n        Exclusion Criteria:\n\n          -  Patients' refusal to participate in the study\n\n          -  Patients unable to give an informed consent\n\n          -  Pregnancy\n\n          -  Emergent surgery\n\n          -  Patient with known  allergy to morphine or paracetamol\n\n          -  Patient with hepatic failure (based on history or elevated liver enzymes).\n\n          -  ASA class >2."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154464", 
            "org_study_id": "SOR 0024-14 CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paracetamol", 
                "intervention_name": "Paracetamol", 
                "intervention_type": "Drug", 
                "other_name": "Perfalgan"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Morphine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Morphine-sparing", 
            "Paracetamol", 
            "Obesity", 
            "Gastric banding"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Alexander Zlotnik, M.D. Ph.D."
            }, 
            "facility": {
                "address": {
                    "city": "Beer Sheva", 
                    "country": "Israel"
                }, 
                "name": "Soroka Medical Center, Ben Gurion University of the Negev"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Morphine-sparing Effect of Intravenous Paracetamol for Post-operative Pain Management Following Laparoscopic Gastric Banding in Morbidly Obese Patients", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Clalit Health Services", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be the comparison amount of morphine injected in each group until discharge", 
            "measure": "amount of morphine", 
            "safety_issue": "No", 
            "time_frame": "Until discharge (participants will be followed for the duration of hospital stay, an expected average of 3 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154464"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Soroka University Medical Center", 
            "investigator_full_name": "Alexander Zlotnik", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Complication during treatment of patient in PACU, including:\nRespiratory complications (respiratory support, need for ICU, etc)\nCardiovascular complications (hemodynamic instability, inotropic support )\nGastrointestinal complications (nausea and vomiting tested by PONV scale, need to use antiemetic drugs)\nIncidence of urinary retention and need for catheterization\nPruritus", 
                "measure": "Complication during treatment of patient in PACU:", 
                "safety_issue": "No", 
                "time_frame": "Until discarge from PACU (participants will be followed for the duration of PACU stay, an expected average of 2 hours)"
            }, 
            {
                "measure": "Time discharging from PACU", 
                "safety_issue": "No", 
                "time_frame": "Until discharge from PACU (participants will be followed for the duration of PACU stay, an expected average of 2 hours)"
            }, 
            {
                "measure": "Length of hospitalization", 
                "safety_issue": "No", 
                "time_frame": "Until discharge from hospital (participants will be followed for the duration of hospital stay, an expected average of 3 days)"
            }, 
            {
                "description": "Complications during hospitalization, including :\nSeptic complications\nRespiratory, cardiac or other complications", 
                "measure": "Complications during hospitalization.", 
                "safety_issue": "No", 
                "time_frame": "Until discharge from hospital (participants will be followed for the duration of hospital stay, an expected average of 3 days)"
            }
        ], 
        "source": "Soroka University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Soroka University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}